Albertsons (ACI) delivered a quarter that matched the numbers but changed the story. Earnings Whispers-normalized EPS of $0.34 topped the $0.31 consensus and matched the $0.34 Earnings Whisper, an in-line result by our measure. Revenue of $18.895 billion edged past the $18.83 billion consensus by 0.3%. Neither figure is what matters. Earnings fell 19.0% year over year and revenue slipped 0.1%. Management also stopped providing a fiscal 2026 outlook and launched a comprehensive business review that puts customer strategy, cost structure, the banner portfolio, markets and capital allocation all under examination. That is the central tension: the quarter landed where management said it would, yet management itself concluded the plan behind those expectations was not good enough.

The quality of the quarter deserves scrutiny. The company reported adjusted EPS of $0.36, versus our normalized $0.34, down from $0.44. GAAP EPS was only $0.11, down from $0.30. The gap reflects $35.3 million of merger-related litigation costs tied to the terminated Kroger deal, $42.4 million of property and impairment losses, and $35.6 million of business-transformation charges.

The per-share decline also understates the erosion:

- Adjusted net income fell about 28%, from $248.4 million to $179.0 million.

- Diluted shares fell roughly 13%, which cushioned the per-share comparison.

- Adjusted EBITDA fell to $784 million from $848.4 million, and the EBITDA margin compressed from 4.5% to 4.1%.

The buybacks carried a balance-sheet cost. Total debt rose to $9.33 billion from $8.13 billion a year earlier, and net debt to EBITDA climbed to 2.42x from 2.02x. Interest expense rose to $125 million from $105 million.

The operating trend is unambiguously weaker:

- **Identical sales:** turned negative at -0.8%, versus +0.7% in fiscal Q4 2025 and +2.4% in fiscal Q3 2025.

- **Core grocery:** down roughly 1.5% excluding pharmacy.

- **Headwinds:** management cited about 210 basis points of drag, including 120 bps from Inflation Reduction Act drug pricing, 30 bps from brand-to-generic conversion, 30 bps from a cyclospora-related produce hit and 30 bps from egg deflation.

- **Digital:** still growing 11%, but slowing from 16% and 21% in the two prior comparison quarters, even as e-commerce penetration rose to 10.5%.

- **Margins:** gross margin ex-fuel and LIFO fell 17 bps on delivery costs and shrink. The SG&A rate ex-fuel deleveraged 38 bps, after improving in prior quarters.

SG&A dollars were held roughly flat, so cost discipline is working. It simply cannot outrun a shrinking sales base. The few bright spots were modest: core grocery improved about 20 bps sequentially from Q1, and pharmacy script growth continued.

The tone shift on the call was stark. Two quarters ago management spoke of "confidence, clarity, momentum." Now the CEO says performance has fallen short and the company carries a cost structure it "can no longer afford." Management also acknowledged that its pricing position is unsatisfactory, while lower-income shoppers are pressured by fuel prices and inflation.

The catalyst list is long but back-end loaded:

- Meg Whitman has been installed as Executive Chair, with "everything on the table."

- The ACI Edge realignment is being accelerated, consolidating 11 divisions into four regions with centralized center-store buying.

- Management signaled a cost-savings ambition beyond the existing $2 billion three-year program.

- Underperforming assets may be exited.

- A refreshed short- and long-term financial framework is promised by the Q4 call, followed by an investor day in spring 2027.

Bears have legitimate ammunition:

- The prior guidance of 0-1% identical sales, $3.85-$3.925 billion adjusted EBITDA and $2.22-$2.32 adjusted EPS is effectively off the table.

- The CFO has departed, and an interim CFO is in place.

- Store exits could bring further charges.

- Rapid restructuring carries execution risk.

- The Kroger litigation remains unresolved.

Investor sentiment, already negative, weakened further from -0.27 to -0.36. That is a meaningful but not dramatic deterioration. The price action tells a more nuanced story. Shares fell to a 52-week low of $10.86 the day after the July report and have since recovered 17.1%. At $12.72, the stock is up 1.8% from the post-report open and sits just 2.4% below its inter-earnings high of $13.03. However, it remains 16.3% below its 200-day moving average of $15.20. The market had already priced in substantial disappointment and appears willing to give the turnaround narrative some benefit of the doubt, even as fundamentals deteriorate.

The bottom line is that Albertsons cleared a lowered bar while conceding that its growth plan no longer works. Negative identical sales, decelerating digital growth, compressing margins and rising leverage define the current business. The value of the stock now hinges on a cost-cutting and portfolio plan that will not be detailed until the fourth-quarter call. Until then, investors are underwriting a turnaround on faith, with no guidance to anchor it.